Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial
- 28 February 2002
- journal article
- Published by Elsevier in Seminars in Oncology
- Vol. 29 (1), 25-29
- https://doi.org/10.1053/sonc.2002.30154
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-TreatmentJournal of Clinical Oncology, 2000
- Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphomaBlood, 2000
- European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic LymphomaJournal of Clinical Oncology, 2000
- Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of RituximabJournal of Clinical Oncology, 1999
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaBlood, 1997